Access to European Union law
<a href="https://eur-lex.europa.eu/content/help/eurlex-content/experimental-features.html" target="_blank">More about the experimental features corner</a>
Choose the experimental features you want to try
EUR-Lex
Access to European Union law

This document is an excerpt from the EUR-Lex website

You are here
Use quotation marks to search for an "exact phrase". Append an asterisk (*) to a search term to find variations of it (transp*, 32019R*). Use a question mark (?) instead of a single character in your search term to find variations of it (ca?e finds case, cane, care).
Search tips
Need more search options? Use the Advanced search

Document C2012/210/09

    Prior notification of a concentration (Case COMP/M.6560 — EQT VI/BSN Medical) Text with EEA relevance

    IO C 210, 17.7.2012, p. 11–11 (BG, ES, CS, DA, DE, ET, EL, EN, FR, IT, LV, LT, HU, MT, NL, PL, PT, RO, SK, SL, FI, SV)

    17.7.2012   

    EN

    Official Journal of the European Union

    C 210/11

    Prior notification of a concentration

    (Case COMP/M.6560 — EQT VI/BSN Medical)

    (Text with EEA relevance)

    2012/C 210/09

    1.

    On 9 July 2012, the Commission received a notification of a proposed concentration pursuant to Article 4 of Council Regulation (EC) No 139/2004 (1) by which the undertaking EQT VI (‘EQT VI’, Guernsey, the UK), part of the EQT group of private equity funds (‘EQT’, Guernsey, the UK), acquires within the meaning of Article 3(1)(b) of the Merger Regulation control of the whole of BSN medical Acquisition Holding GmbH (‘BSN medical Acquisition Holding’, Germany) and BSN medical Netherlands Holding BV BSN medical Netherlands (‘BSN medical Netherlands’, the Netherlands) and their respective subsidiaries (collectively ‘BSN Medical’) by way of purchase of shares.

    2.

    The business activities of the undertakings concerned are:

    —

    EQT VI: investment fund making investments primarily in Northern Europe,

    —

    EQT: a group of private equity funds, which are managed independently and on their merits and are not, even within respective fund, financially or operationally consolidated,

    —

    BSN Medical: a medical device company that develops, manufactures and markets wound care, compression therapy and orthopedics products.

    3.

    On preliminary examination, the Commission finds that the notified transaction could fall within the scope the EC Merger Regulation. However, the final decision on this point is reserved.

    4.

    The Commission invites interested third parties to submit their possible observations on the proposed operation to the Commission.

    Observations must reach the Commission not later than 10 days following the date of this publication. Observations can be sent to the Commission by fax (+32 22964301), by e-mail to COMP-MERGER-REGISTRY@ec.europa.eu or by post, under reference number COMP/M.6560 — EQT VI/BSN Medical, to the following address:

    European Commission

    Directorate-General for Competition

    Merger Registry

    J-70

    1049 Bruxelles/Brussel

    BELGIQUE/BELGIË

    (1)  OJ L 24, 29.1.2004, p. 1 (the ‘EC Merger Regulation’).

    Top